anxiety disorder	1	1.7275	1	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	
relevant treatment	0	1.5969	4	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
treatment manual(s)	0	1.5969	4	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
marketing authorisation	0	1.5204	2	This guideline recommends some drugs for indications for which they do not have a UK marketing authorisation at the date of publication, if they are already in use in the NHS for that indication, and there is good evidence to support that use	UK marketing authorisation for depression or the indication stated at the time of publication.	
st john	0	1.5204	1	Although there is evidence that St John's wort may be of benefit in mild or moderate depression, practitioners should: not prescribe or advise its use by people with depression because of uncertainty about appropriate doses, persistence of effect, variation in the nature of preparations and potential serious interactions with other drugs (including oral contraceptives, anticoagulants and anticonvulsants) advise people with depression of the different potencies of the preparations available and of the potential serious interactions of St John's wort with other drugs.	
uk marketing	0	1.5204	2	This guideline recommends some drugs for indications for which they do not have a UK marketing authorisation at the date of publication, if they are already in use in the NHS for that indication, and there is good evidence to support that use	UK marketing authorisation for depression or the indication stated at the time of publication.	
behavioural therapy	0	1.4671	3	The efficacy and cost effectiveness of cognitive behavioural therapy, interpersonal therapy and 0 The effectiveness of maintenance ECT for relapse prevention in people with severe and recurring	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	
cognitive behavioural	0	1.4671	3	The efficacy and cost effectiveness of cognitive behavioural therapy, interpersonal therapy and 0 The effectiveness of maintenance ECT for relapse prevention in people with severe and recurring	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	
psychodynamic psychotherapy	0	1.4584	2	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with mild to moderate depression having short-term psychodynamic psychotherapy, the duration of treatment should typically be in the range of 16 to 20 sessions over 4 to 6 months.	
short-term psychodynamic	0	1.4584	2	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with mild to moderate depression having short-term psychodynamic psychotherapy, the duration of treatment should typically be in the range of 16 to 20 sessions over 4 to 6 months.	
antidepressant treatment	0	1.4334	5	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	A person with depression started on antidepressants who is considered to present an increased suicide risk or is younger than 30 years (because of the potential increased prevalence of suicidal thoughts in the early stages of antidepressant treatment for this group) should normally be seen after 1 week and frequently thereafter as appropriate until the risk is no longer considered clinically important.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	
residual symptoms	0	1.4333	3	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Treatment choice should be influenced by: previous treatment history, including the consequences of a relapse, residual symptoms, response to previous treatment and any discontinuation symptoms the person's preference.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	
previous treatments	0	1.4142	2	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	In specialist mental health services, after thoroughly reviewing previous treatments for depression, consider reintroducing previous treatments that have been inadequately delivered or adhered to.	
concomitant medication	0	1.3948	2	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	When prescribing antidepressants for older people: prescribe at an age-appropriate dose taking into account the effect of general physical health and concomitant medication on pharmacokinetics and pharmacodynamics	
group-based cbt	0	1.3948	2	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	
suspected depression	0	1.3948	2	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	When assessing a person with suspected depression, consider using a validated measure (for example, for symptoms, functions and or disability) to inform and evaluate treatment.	
treatment options	0	1.3948	4	Erectile dysfunction 3 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 4 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 5 Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications. 6 Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	Erectile dysfunction 3 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 4 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 5 Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications. 6 Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	Last updated April 2018 explore treatment options in an atmosphere of hope and optimism, explaining the different courses of depression and that recovery is possible be aware that stigma and discrimination can be associated with a diagnosis of depression ensure that discussions take place in settings in which confidentiality, privacy and dignity are respected.	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	
multiprofessional care	0	1.3491	2	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	
previous treatment	0	1.323	5	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	Treatment choice should be influenced by: previous treatment history, including the consequences of a relapse, residual symptoms, response to previous treatment and any discontinuation symptoms the person's preference.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	In specialist mental health services, after thoroughly reviewing previous treatments for depression, consider reintroducing previous treatments that have been inadequately delivered or adhered to.	ECT, consider a repeat trial of ECT only after: reviewing the adequacy of the previous treatment course and considering all other options and discussing the risks and benefits with the person and or, where appropriate, their advoc	
psychological intervention	0	1.3134	13	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	Psychological interventions for relapse prevention	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	For all high-intensity psychological interventions, the duration of treatment should normally be within the limits indicated in this guideline	Combined psychological and drug treatment 0 For a person whose depression has not responded to either pharmacological or psychological interventions, consider combining antidepressant medication with CBT.	Psychological interventions for relapse prevention	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Delivering psychological interventions for relapse prevention	The full range of high-intensity psychological interventions should normally be offered in inpatient settings	
health services	1	1.3086	9	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	If a person with depression presents considerable immediate risk to themselves or others, refer them urgently to specialist mental health services.	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	In specialist mental health services, after thoroughly reviewing previous treatments for depression, consider reintroducing previous treatments that have been inadequately delivered or adhered to.	Medication in secondary care mental health services should be started under the supervision of a consultant psychiatrist.	
specialist mental	0	1.3086	7	If a person with depression presents considerable immediate risk to themselves or others, refer them urgently to specialist mental health services.	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	In specialist mental health services, after thoroughly reviewing previous treatments for depression, consider reintroducing previous treatments that have been inadequately delivered or adhered to.	
competent practitioners	0	1.2753	3	All interventions for depression should be delivered by competent practitioners	All interventions for depression should be delivered by competent practitioners.	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	
drug treatment	0	1.2488	27	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 7 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Initial drug treatment 9 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 0 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute 3m2. 3 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 4 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	First intensification of drug treatment 5 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 6 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 7 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Initial drug treatment 9 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 0 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute 3m2. 3 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 4 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	First intensification of drug treatment 5 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 6 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	Combined psychological and drug treatment 0 For a person whose depression has not responded to either pharmacological or psychological interventions, consider combining antidepressant medication with CBT.	Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.	
appraisal guidance	0	1.2333	4	Section of this guideline updates recommendations made in 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59) for the treatment of depression only	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	The recommendations in this section update the depression aspects only of 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59).	
nice technology	0	1.2333	4	Section of this guideline updates recommendations made in 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59) for the treatment of depression only	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	The recommendations in this section update the depression aspects only of 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59).	
technology appraisal	0	1.2333	4	Section of this guideline updates recommendations made in 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59) for the treatment of depression only	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	The recommendations in this section update the depression aspects only of 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59).	
depression identification	0	1.2329	2	If a person answers 'yes' to either of the depression identification questions (see recommendation ) but the practitioner is not competent to perform a mental health assessment, they should refer the person to an appropriate professional	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	
health assessment	0	1.2329	2	If a person answers 'yes' to either of the depression identification questions (see recommendation ) but the practitioner is not competent to perform a mental health assessment, they should refer the person to an appropriate professional	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	
identification questions	0	1.2329	2	If a person answers 'yes' to either of the depression identification questions (see recommendation ) but the practitioner is not competent to perform a mental health assessment, they should refer the person to an appropriate professional	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	
person answers	0	1.2329	2	If a person answers 'yes' to either of the depression identification questions (see recommendation ) but the practitioner is not competent to perform a mental health assessment, they should refer the person to an appropriate professional	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	
activity programmes	0	1.2263	1	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	
additional social	0	1.2263	1	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
adverse events	0	1.2263	1	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	
age-appropriate dose	0	1.2263	1	When prescribing antidepressants for older people: prescribe at an age-appropriate dose taking into account the effect of general physical health and concomitant medication on pharmacokinetics and pharmacodynamics	
anti-inflammatory drugs	0	1.2263	1	In particular, consider prescribing a gastroprotective drug in older people who are taking non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin.	
anticipated adverse	0	1.2263	1	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	
antipsychotic medication	0	1.2263	1	For people who have depression with psychotic symptoms, consider augmenting the current treatment plan with antipsychotic medication (although the optimum dose and duration of treatment are unknown).	
behavioural principles	0	1.2263	1	Behavioural couples therapy for depression should normally be based on behavioural principles, and an adequate course of therapy should be 15 to 20 sessions over 5 to 6 months.	
british national	1	1.2263	1	The guideline assumes that prescribers will use a drug's summary of product characteristics (SPC) and the 'British national formulary' (BNF) to inform their decisions made with individual patients.	
care mental	1	1.2263	1	Medication in secondary care mental health services should be started under the supervision of a consultant psychiatrist.	
clear information	0	1.2263	1	Ensure that consent to treatment is based on the provision of clear information (which should also be available in written form) about the intervention, covering: what it comprises what is expected of the person while having it likely outcomes (including any side effects).	
cognitive impairments	0	1.2263	1	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	
combined psychological	0	1.2263	1	Combined psychological and drug treatment 0 For a person whose depression has not responded to either pharmacological or psychological interventions, consider combining antidepressant medication with CBT.	
communication difficulties	0	1.2263	1	For people with significant language or communication difficulties, for example people with sensory impairments or a learning disability, consider using the	
competent practitioner	0	1.2263	4	All interventions for depression should be delivered by competent practitioners	All interventions for depression should be delivered by competent practitioners.	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	
complete relief	0	1.2263	1	Where possible, the key goal of an intervention should be complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.	
complex intervention	0	1.2263	1	It is likely to be effective only when provided as part of a more complex intervention.	
complex multiprofessional	0	1.2263	1	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	
considerable time	0	1.2263	1	Symptoms are considered persistent if they continue despite active monitoring and or low-intensity intervention, or have been present for a considerable time, typically several months (For a diagnosis of dysthymia, symptoms should be present for at least 2 years .)	
current treatment	0	1.2263	1	For people who have depression with psychotic symptoms, consider augmenting the current treatment plan with antipsychotic medication (although the optimum dose and duration of treatment are unknown).	
day symptoms	0	1.2263	0	
depression referral	0	1.2263	0	
depression short-term	0	1.2263	1	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	
discuss antidepressant	0	1.2263	1	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	
drug treatments	0	1.2263	3	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.	
effects person	0	1.2263	1	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	
expert opinion	1	1.2263	1	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	
follow-up appointments	0	1.2263	1	Last updated April 2018 provide information about the nature and course of depression arrange a further assessment, normally within 2 weeks make contact if the person does not attend follow-up appointments.	
full range	0	1.2263	1	The full range of high-intensity psychological interventions should normally be offered in inpatient settings	
gastroprotective drug	0	1.2263	1	In particular, consider prescribing a gastroprotective drug in older people who are taking non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin.	
general physical	0	1.2263	1	When prescribing antidepressants for older people: prescribe at an age-appropriate dose taking into account the effect of general physical health and concomitant medication on pharmacokinetics and pharmacodynamics	
health problems	0	1.2263	1	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	
health professionals	0	1.2263	1	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	
high-priority routine	0	1.2263	1	The teams should monitor risk as a high-priority routine activity in a way that allows people to continue their lives without disruption.	
individual patients	0	1.2263	1	The guideline assumes that prescribers will use a drug's summary of product characteristics (SPC) and the 'British national formulary' (BNF) to inform their decisions made with individual patients.	
information section	0	1.2263	1	The update information section has a list of recommendations for which the evidence has not been updated since the original guideline.	
inpatient settings	0	1.2263	1	The full range of high-intensity psychological interventions should normally be offered in inpatient settings	
inpatient treatment	0	1.2263	1	Consider inpatient treatment for people with depression who are at significant risk of suicide, self-harm or self-neglect.	
key goal	0	1.2263	1	Where possible, the key goal of an intervention should be complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.	
long-standing moderate	0	1.2263	1	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
low-intensity intervention	0	1.2263	1	Symptoms are considered persistent if they continue despite active monitoring and or low-intensity intervention, or have been present for a considerable time, typically several months (For a diagnosis of dysthymia, symptoms should be present for at least 2 years .)	
medication management	0	1.2263	1	Medication management as a separate intervention for people with depression should not be provided routinely by services	
moderate duration	0	1.2263	1	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	
monoamine oxidase	1	1.2263	1	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	
multiple drug	0	1.2263	1	Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.	
national formulary	0	1.2263	1	The guideline assumes that prescribers will use a drug's summary of product characteristics (SPC) and the 'British national formulary' (BNF) to inform their decisions made with individual patients.	
non-reversible monoamine	0	1.2263	1	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	
non-steroidal anti-inflammatory	0	1.2263	1	In particular, consider prescribing a gastroprotective drug in older people who are taking non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin.	
optimum dose	0	1.2263	1	For people who have depression with psychotic symptoms, consider augmenting the current treatment plan with antipsychotic medication (although the optimum dose and duration of treatment are unknown).	
original guideline	0	1.2263	1	The update information section has a list of recommendations for which the evidence has not been updated since the original guideline.	
oxidase inhibitors	0	1.2263	1	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	
pharmacodynamics depression	0	1.2263	0	
potential adverse	0	1.2263	1	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	
potential interactions	0	1.2263	1	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	
product characteristics	0	1.2263	5	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	The guideline assumes that prescribers will use a drug's summary of product characteristics (SPC) and the 'British national formulary' (BNF) to inform their decisions made with individual patients.	
psychological treatment	0	1.2263	2	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.	
psychological treatments	0	1.2263	1	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
rehabilitation programme	0	1.2263	1	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
relative advantage	0	1.2263	1	When switching to another antidepressant, be aware that the evidence for the relative advantage of switching either within or between classes is weak.	
relevant specialist	0	1.2263	1	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	
risk assessment	0	1.2263	1	Risk assessment and monitoring	
routine activity	0	1.2263	1	The teams should monitor risk as a high-priority routine activity in a way that allows people to continue their lives without disruption.	
sensory impairments	0	1.2263	1	For people with significant language or communication difficulties, for example people with sensory impairments or a learning disability, consider using the	
separate intervention	0	1.2263	1	Medication management as a separate intervention for people with depression should not be provided routinely by services	
significant language	0	1.2263	1	For people with significant language or communication difficulties, for example people with sensory impairments or a learning disability, consider using the	
social activities	0	1.2263	1	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
structured model	0	1.2263	1	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	
sufficient severity	0	1.2263	1	Symptoms should be present for at least 2 weeks and each symptom should be present at sufficient severity for most of every day	
symptoms previous	0	1.2263	1	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	
trained volunteers	0	1.2263	1	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
treatment likelihood	0	1.2263	1	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	
treatment plan	0	1.2263	3	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	For people who have depression with psychotic symptoms, consider augmenting the current treatment plan with antipsychotic medication (although the optimum dose and duration of treatment are unknown).	
treatment preference	0	1.2263	1	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	
update information	0	1.2263	1	The update information section has a list of recommendations for which the evidence has not been updated since the original guideline.	
vocational support	0	1.2263	1	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
weekly contact	0	1.2263	1	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
written form	0	1.2263	1	Ensure that consent to treatment is based on the provision of clear information (which should also be available in written form) about the intervention, covering: what it comprises what is expected of the person while having it likely outcomes (including any side effects).	
behavioural couples	0	1.2155	3	IPT) behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic benefit.	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	Behavioural couples therapy for depression should normally be based on behavioural principles, and an adequate course of therapy should be 15 to 20 sessions over 5 to 6 months.	
couples therapy	0	1.2155	3	IPT) behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic benefit.	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	Behavioural couples therapy for depression should normally be based on behavioural principles, and an adequate course of therapy should be 15 to 20 sessions over 5 to 6 months.	
account toxicity	0	1.211	1	If a person with depression is assessed to be at risk of suicide: take into account toxicity in overdose if an antidepressant is prescribed or the person is taking other medication; if necessary, limit the amount of drug(s) available	
frequent direct	0	1.211	1	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	
telephone contacts	0	1.211	1	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	
mild depression	0	1.209	3	In practical terms, clinicians are not expected to switch to DSM-IV but should be aware that the threshold for mild depression is higher than ICD-10 (five symptoms instead of four) and that degree of functional impairment should be routinely assessed before making a diagnosis	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	
other disorders	1	1.1999	1	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	
primary diagnosis	0	1.1999	1	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	
relevant nice	0	1.1999	1	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	
topic page	0	1.1999	1	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	
suicidal ideation	0	1.195	2	Advise people with depression of the potential for increased agitation, anxiety and suicidal ideation in the initial stages of treatment; actively seek out these symptoms and: ensure that the person knows how to seek help promptly review the person's treatment if they develop marked and or prolonged agitation.	Advise a person with depression and their family or carer to be vigilant for mood changes, negativity and hopelessness, and suicidal ideation, and to contact their practitioner if concerned	
antidepressant medication	0	1.1936	5	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	Combined psychological and drug treatment 0 For a person whose depression has not responded to either pharmacological or psychological interventions, consider combining antidepressant medication with CBT.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	
secondary care	0	1.1921	3	This guideline covers identifying and managing depression in adults aged 18 years and older, in primary and secondary care	This guideline makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older, in primary and secondary care	Medication in secondary care mental health services should be started under the supervision of a consultant psychiatrist.	
discontinuation symptoms	0	1.184	5	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	Treatment choice should be influenced by: previous treatment history, including the consequences of a relapse, residual symptoms, response to previous treatment and any discontinuation symptoms the person's preference.	Inform the person that they should seek advice from their practitioner if they experience significant discontinuation symptoms	If discontinuation symptoms occur: monitor symptoms and reassure the person if symptoms are mild consider reintroducing the original antidepressant at the dose that was effective (or another antidepressant with a longer half-life from the same class) if symptoms are severe, and reduce the dose gradually while monitoring symptoms. 0 Step 4: complex and severe depression	
nice guidelines	0	1.1756	6	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.	
collaborative care	0	1.1616	2	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	
complex problems	0	1.1616	1	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	
identification treatment	0	1.1402	1	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	
adverse effects	0	1.1347	2	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the risk–benefit ratio is unclear document the rationale for the chosen combination.	
consultant psychiatrist	0	1.1347	2	When using combinations of medications (which should only normally be started in primary care in consultation with a consultant psychiatrist): select medications that are known to be safe when used together be aware of the increased side-effect burden this usually causes discuss the rationale for any combination with the person with depression, follow	Medication in secondary care mental health services should be started under the supervision of a consultant psychiatrist.	
chronic physical	0	1.1343	8	NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91), which makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Refer to 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) for further information.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	
health problem	0	1.1343	9	NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91), which makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	Refer to 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) for further information.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	
significant risk	0	1.1212	4	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	Consider inpatient treatment for people with depression who are at significant risk of suicide, self-harm or self-neglect.	
clinical guideline	0	1.1171	4	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91), which makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Refer to 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) for further information.	
nice clinical	0	1.1171	4	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91), which makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Refer to 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) for further information.	
physical activity	0	1.1159	5	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	
treatment plans	0	1.1114	2	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	
side-effect burden	0	1.1088	3	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	When using combinations of medications (which should only normally be started in primary care in consultation with a consultant psychiatrist): select medications that are known to be safe when used together be aware of the increased side-effect burden this usually causes discuss the rationale for any combination with the person with depression, follow	If a person with depression is informed about, and prepared to tolerate, the increased side-effect burden, consider combining or augmenting an antidepressant with: lithium or an antipsychotic such as aripiprazole , olanzapine , quetiapine or risperidone or another antidepressant such as mirtazapine or mianserin.	
subthreshold depressive	0	1.1016	11	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with persistent subthreshold depressive symptoms or mild to moderate depression having counselling, the duration of treatment should typically be in the range of six to ten sessions over 8 to 12 weeks.	
reviews progress	0	1.0964	2	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	Last updated April 2018 outcomes be supported by a trained practitioner, who typically provides limited facilitation of the programme and reviews progress and outcome typically take place over 9 to 12 weeks, including follow-up.	
trained practitioner	0	1.0964	2	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	Last updated April 2018 outcomes be supported by a trained practitioner, who typically provides limited facilitation of the programme and reviews progress and outcome typically take place over 9 to 12 weeks, including follow-up.	
behavioural activation	0	1.0929	3	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with depression having behavioural activation, the duration of treatment should typically be in the range of 16 to 20 sessions over 3 to 4 months	
psychological interventions	0	1.0794	10	Psychological interventions for relapse prevention	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions	For all high-intensity psychological interventions, the duration of treatment should normally be within the limits indicated in this guideline	Combined psychological and drug treatment 0 For a person whose depression has not responded to either pharmacological or psychological interventions, consider combining antidepressant medication with CBT.	Psychological interventions for relapse prevention	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Delivering psychological interventions for relapse prevention	The full range of high-intensity psychological interventions should normally be offered in inpatient settings	
physical health	0	1.0782	10	NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91), which makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	Refer to 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) for further information.	When prescribing antidepressants for older people: prescribe at an age-appropriate dose taking into account the effect of general physical health and concomitant medication on pharmacokinetics and pharmacodynamics	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	
active monitoring	0	1.0592	3	Symptoms are considered persistent if they continue despite active monitoring and or low-intensity intervention, or have been present for a considerable time, typically several months (For a diagnosis of dysthymia, symptoms should be present for at least 2 years .)	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	
depression aspects	0	1.0564	1	The recommendations in this section update the depression aspects only of 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59).	
inform people	0	1.0496	1	Inform people with depression about self-help groups, support groups and other local and national resources.	
national resources	1	1.0496	1	Inform people with depression about self-help groups, support groups and other local and national resources.	
self-help groups	0	1.0496	1	Inform people with depression about self-help groups, support groups and other local and national resources.	
mental health	1	1.0431	15	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	If a person answers 'yes' to either of the depression identification questions (see recommendation ) but the practitioner is not competent to perform a mental health assessment, they should refer the person to an appropriate professional	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	If a person with depression presents considerable immediate risk to themselves or others, refer them urgently to specialist mental health services.	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	In specialist mental health services, after thoroughly reviewing previous treatments for depression, consider reintroducing previous treatments that have been inadequately delivered or adhered to.	Medication in secondary care mental health services should be started under the supervision of a consultant psychiatrist.	
cbt model	0	1.043	1	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	
limited facilitation	0	1.043	1	Last updated April 2018 outcomes be supported by a trained practitioner, who typically provides limited facilitation of the programme and reviews progress and outcome typically take place over 9 to 12 weeks, including follow-up.	
stand-alone computer-based	0	1.043	1	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	
web-based programme	0	1.043	1	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	
cognitive impairment	1	1.0352	2	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	When providing interventions for people with a learning disability or acquired cognitive impairment who have a diagnosis of depression: where possible, provide the same interventions as for other people with depression if necessary, adjust the method of delivery or duration of the intervention to take account of the disability or impairment.	
depressive symptoms	0	1.0325	12	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with persistent subthreshold depressive symptoms or mild to moderate depression having counselling, the duration of treatment should typically be in the range of six to ten sessions over 8 to 12 weeks.	
early stages	0	1.0256	1	A person with depression started on antidepressants who is considered to present an increased suicide risk or is younger than 30 years (because of the potential increased prevalence of suicidal thoughts in the early stages of antidepressant treatment for this group) should normally be seen after 1 week and frequently thereafter as appropriate until the risk is no longer considered clinically important.	
suicidal thoughts	0	1.0256	1	A person with depression started on antidepressants who is considered to present an increased suicide risk or is younger than 30 years (because of the potential increased prevalence of suicidal thoughts in the early stages of antidepressant treatment for this group) should normally be seen after 1 week and frequently thereafter as appropriate until the risk is no longer considered clinically important.	
suicide risk	0	1.0193	2	A person with depression started on antidepressants who is considered to present an increased suicide risk or is younger than 30 years (because of the potential increased prevalence of suicidal thoughts in the early stages of antidepressant treatment for this group) should normally be seen after 1 week and frequently thereafter as appropriate until the risk is no longer considered clinically important.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	
high-intensity psychological	0	1.0171	6	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	For all high-intensity psychological interventions, the duration of treatment should normally be within the limits indicated in this guideline	The full range of high-intensity psychological interventions should normally be offered in inpatient settings	
alternative antidepressant	0	1.0084	1	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	
check adherence	0	1.0084	1	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	
combination medication	0	1.0084	1	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	
initial pharmacological	0	1.0084	1	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	
initial treatment	0	1.0084	1	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	
outcome measure	0	1.0084	3	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	
outcome monitoring	0	1.0084	1	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	
pharmacological interventions	0	1.0084	1	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	
single antidepressant	0	1.0084	1	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	
chronic symptoms	0	0.9997	1	Last updated April 2018 treatment, provide appropriate information and consider one of the following strategies: monitor symptoms closely where side effects are mild and acceptable to the person or stop the antidepressant or change to a different antidepressant if the person prefers or in discussion with the person, consider short-term concomitant treatment with a benzodiazepine if anxiety, agitation and or insomnia are problematic (except in people with chronic symptoms of anxiety); this should usually be for no longer than 2 weeks in order to prevent the development of dependence.	
concomitant treatment	0	0.9997	1	Last updated April 2018 treatment, provide appropriate information and consider one of the following strategies: monitor symptoms closely where side effects are mild and acceptable to the person or stop the antidepressant or change to a different antidepressant if the person prefers or in discussion with the person, consider short-term concomitant treatment with a benzodiazepine if anxiety, agitation and or insomnia are problematic (except in people with chronic symptoms of anxiety); this should usually be for no longer than 2 weeks in order to prevent the development of dependence.	
short-term concomitant	0	0.9997	1	Last updated April 2018 treatment, provide appropriate information and consider one of the following strategies: monitor symptoms closely where side effects are mild and acceptable to the person or stop the antidepressant or change to a different antidepressant if the person prefers or in discussion with the person, consider short-term concomitant treatment with a benzodiazepine if anxiety, agitation and or insomnia are problematic (except in people with chronic symptoms of anxiety); this should usually be for no longer than 2 weeks in order to prevent the development of dependence.	
psychotic symptoms	0	0.9918	4	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	For people who have depression with psychotic symptoms, consider augmenting the current treatment plan with antipsychotic medication (although the optimum dose and duration of treatment are unknown).	
activity programme	0	0.9833	3	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	
group physical	0	0.9833	2	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	
structured group	0	0.9833	2	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	
atypical symptoms	0	0.9792	1	IV is used in nearly all the evidence reviewed and it provides definitions for atypical symptoms and seasonal depression	
careful review	0	0.9792	1	After careful review of the diagnostic criteria and the evidence, the	
classificatory systems	0	0.9792	1	It should be noted that classificatory systems are agreed conventions that seek to define different severities of depression in order to guide diagnosis and treatment, and their value is determined by how useful they are in practice	
diagnostic assessment	0	0.9792	1	Therefore it is also important to consider both personal past history and family history of depression when undertaking a diagnostic assessment (see appendix for further details).	
diagnostic criteria	0	0.9792	1	After careful review of the diagnostic criteria and the evidence, the	
family history	0	0.9792	1	Therefore it is also important to consider both personal past history and family history of depression when undertaking a diagnostic assessment (see appendix for further details).	
personal past	0	0.9792	1	Therefore it is also important to consider both personal past history and family history of depression when undertaking a diagnostic assessment (see appendix for further details).	
practical terms	0	0.9792	1	In practical terms, clinicians are not expected to switch to DSM-IV but should be aware that the threshold for mild depression is higher than ICD-10 (five symptoms instead of four) and that degree of functional impairment should be routinely assessed before making a diagnosis	
seasonal depression	0	0.9792	1	IV is used in nearly all the evidence reviewed and it provides definitions for atypical symptoms and seasonal depression	
alternative media	0	0.9764	1	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	
reading age	0	0.9764	1	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	
self-help programme	0	0.9764	1	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	
self-help programmes	0	0.9764	1	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	
written materials	0	0.9764	1	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	
comprehensive assessment	0	0.9737	3	When assessing a person who may have depression, conduct a comprehensive assessment that does not rely simply on a symptom count	Note that a comprehensive assessment of depression should not rely simply on a symptom count, but should take into account the degree of functional impairment and or disability (see section ).	When assessing a person who may have depression, conduct a comprehensive assessment that does not rely simply on a symptom count	
symptom count	0	0.9737	3	When assessing a person who may have depression, conduct a comprehensive assessment that does not rely simply on a symptom count	Note that a comprehensive assessment of depression should not rely simply on a symptom count, but should take into account the degree of functional impairment and or disability (see section ).	When assessing a person who may have depression, conduct a comprehensive assessment that does not rely simply on a symptom count	
electroconvulsive therapy	0	0.9566	2	Section of this guideline updates recommendations made in 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59) for the treatment of depression only	The recommendations in this section update the depression aspects only of 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59).	
low-intensity psychosocial	0	0.9539	3	Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	
original antidepressant	0	0.9489	1	If discontinuation symptoms occur: monitor symptoms and reassure the person if symptoms are mild consider reintroducing the original antidepressant at the dose that was effective (or another antidepressant with a longer half-life from the same class) if symptoms are severe, and reduce the dose gradually while monitoring symptoms. 0 Step 4: complex and severe depression	
significant discontinuation	0	0.9489	1	Inform the person that they should seek advice from their practitioner if they experience significant discontinuation symptoms	
persistent subthreshold	0	0.9466	11	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with persistent subthreshold depressive symptoms or mild to moderate depression having counselling, the duration of treatment should typically be in the range of six to ten sessions over 8 to 12 weeks.	
moderate depression	0	0.946	13	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	Although there is evidence that St John's wort may be of benefit in mild or moderate depression, practitioners should: not prescribe or advise its use by people with depression because of uncertainty about appropriate doses, persistence of effect, variation in the nature of preparations and potential serious interactions with other drugs (including oral contraceptives, anticoagulants and anticonvulsants) advise people with depression of the different potencies of the preparations available and of the potential serious interactions of St John's wort with other drugs.	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with persistent subthreshold depressive symptoms or mild to moderate depression having counselling, the duration of treatment should typically be in the range of six to ten sessions over 8 to 12 weeks.	For all people with mild to moderate depression having short-term psychodynamic psychotherapy, the duration of treatment should typically be in the range of 16 to 20 sessions over 4 to 6 months.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.	
2-week washout	0	0.9446	1	Last updated April 2018 from a non-reversible MAOI: a 2-week washout period is required (other antidepressants should not be prescribed routinely during this period).	
non-reversible maoi	0	0.9446	1	Last updated April 2018 from a non-reversible MAOI: a 2-week washout period is required (other antidepressants should not be prescribed routinely during this period).	
short half-life	0	0.9446	1	When switching to another antidepressant, which can normally be achieved within 1 week when switching from drugs with a short half-life, consider the potential for interactions in determining the choice of new drug and the nature and duration of the transition	
transition depression	0	0.9446	0	
washout period	0	0.9446	1	Last updated April 2018 from a non-reversible MAOI: a 2-week washout period is required (other antidepressants should not be prescribed routinely during this period).	
behaviour therapy	0	0.9423	2	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	
cognitive behaviour	0	0.9423	5	The efficacy and cost effectiveness of cognitive behavioural therapy, interpersonal therapy and 0 The effectiveness of maintenance ECT for relapse prevention in people with severe and recurring	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	
computerised cognitive	0	0.9423	4	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	
advise people	0	0.9391	2	Advise people with depression of the potential for increased agitation, anxiety and suicidal ideation in the initial stages of treatment; actively seek out these symptoms and: ensure that the person knows how to seek help promptly review the person's treatment if they develop marked and or prolonged agitation.	Although there is evidence that St John's wort may be of benefit in mild or moderate depression, practitioners should: not prescribe or advise its use by people with depression because of uncertainty about appropriate doses, persistence of effect, variation in the nature of preparations and potential serious interactions with other drugs (including oral contraceptives, anticoagulants and anticonvulsants) advise people with depression of the different potencies of the preparations available and of the potential serious interactions of St John's wort with other drugs.	
initial stages	0	0.9391	1	Advise people with depression of the potential for increased agitation, anxiety and suicidal ideation in the initial stages of treatment; actively seek out these symptoms and: ensure that the person knows how to seek help promptly review the person's treatment if they develop marked and or prolonged agitation.	
prolonged agitation	0	0.9391	1	Advise people with depression of the potential for increased agitation, anxiety and suicidal ideation in the initial stages of treatment; actively seek out these symptoms and: ensure that the person knows how to seek help promptly review the person's treatment if they develop marked and or prolonged agitation.	
combination treatments	0	0.9349	1	Referral 1 For a person whose depression has failed to respond to various strategies for augmentation and combination treatments, consider referral to a practitioner with a specialist interest in treating depression, or to a specialist service.	
specialist interest	0	0.9349	1	Referral 1 For a person whose depression has failed to respond to various strategies for augmentation and combination treatments, consider referral to a practitioner with a specialist interest in treating depression, or to a specialist service.	
specialist service	0	0.9349	3	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	Referral 1 For a person whose depression has failed to respond to various strategies for augmentation and combination treatments, consider referral to a practitioner with a specialist interest in treating depression, or to a specialist service.	
effective antidepressants	0	0.9239	1	Be aware that: compared with other equally effective antidepressants recommended for routine use in primary care, venlafaxine is associated with a greater risk of death from overdose tricyclic antidepressants (TCAs), except for lofepramine, are associated with the greatest risk in overdose.	
overdose tricyclic	0	0.9239	1	Be aware that: compared with other equally effective antidepressants recommended for routine use in primary care, venlafaxine is associated with a greater risk of death from overdose tricyclic antidepressants (TCAs), except for lofepramine, are associated with the greatest risk in overdose.	
tricyclic antidepressants	0	0.9239	1	Be aware that: compared with other equally effective antidepressants recommended for routine use in primary care, venlafaxine is associated with a greater risk of death from overdose tricyclic antidepressants (TCAs), except for lofepramine, are associated with the greatest risk in overdose.	
treatment history	0	0.9224	2	Treatment choice should be influenced by: previous treatment history, including the consequences of a relapse, residual symptoms, response to previous treatment and any discontinuation symptoms the person's preference.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	
side effects	0	0.9216	11	Initial drug treatment 9 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 0 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Initial drug treatment 9 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 0 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Ensure that consent to treatment is based on the provision of clear information (which should also be available in written form) about the intervention, covering: what it comprises what is expected of the person while having it likely outcomes (including any side effects).	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	Last updated April 2018 treatment, provide appropriate information and consider one of the following strategies: monitor symptoms closely where side effects are mild and acceptable to the person or stop the antidepressant or change to a different antidepressant if the person prefers or in discussion with the person, consider short-term concomitant treatment with a benzodiazepine if anxiety, agitation and or insomnia are problematic (except in people with chronic symptoms of anxiety); this should usually be for no longer than 2 weeks in order to prevent the development of dependence.	People who start on low-dose TCAs and who have a clear clinical response can be maintained on that dose with careful monitoring. 0 If the person's depression shows no improvement after 2 to 4 weeks with the first antidepressant, check that the drug has been taken regularly and in the prescribed dose. 1 If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers. 2 If the person's depression shows some improvement by 4 weeks, continue treatment for another 2 to 4 weeks	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	People who have had multiple episodes of depression, and who have had a good response to treatment with an antidepressant and an augmenting agent, should remain on this combination after remission if they find the side effects tolerable and acceptable	
mental capacity	0	0.9208	1	Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.	
professional guidelines	0	0.9208	1	Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.	
primary care	1	0.9162	2	Be aware that: compared with other equally effective antidepressants recommended for routine use in primary care, venlafaxine is associated with a greater risk of death from overdose tricyclic antidepressants (TCAs), except for lofepramine, are associated with the greatest risk in overdose.	When using combinations of medications (which should only normally be started in primary care in consultation with a consultant psychiatrist): select medications that are known to be safe when used together be aware of the increased side-effect burden this usually causes discuss the rationale for any combination with the person with depression, follow	
previous episodes	0	0.9111	2	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	
significant history	0	0.9111	2	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	
treatment mindfulness-based	0	0.9111	2	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	
support groups	0	0.9058	2	Inform people with depression about self-help groups, support groups and other local and national resources.	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	
follow-up sessions	0	0.9011	4	Also consider providing: two sessions per week for the first 2 to 3 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	Also consider providing: two sessions per week for the first 3 to 4 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	If the duration of treatment needs to be extended to achieve remission it should: consist of two sessions per week for the first 2 to 3 weeks of treatment include additional follow-up sessions, typically consisting of four to six sessions over	Last updated April 2018 the following 6 months. 0 Mindfulness-based cognitive therapy should normally be delivered in groups of 8 to 15 participants and consist of weekly 2-hour meetings over 8 weeks and four follow-up sessions in the 12 months after the end of treatment.	
initial presentation	0	0.8996	2	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	
long period	0	0.8996	2	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	
relapse prevention	0	0.8781	8	The efficacy and cost effectiveness of cognitive behavioural therapy, interpersonal therapy and 0 The effectiveness of maintenance ECT for relapse prevention in people with severe and recurring	Continuation and relapse prevention	Psychological interventions for relapse prevention	Continuation and relapse prevention	Using medication for relapse prevention	Psychological interventions for relapse prevention	Delivering psychological interventions for relapse prevention	For all people with depression who are having individual CBT for relapse prevention, the duration of treatment should typically be in the range of 16 to 20 sessions over 3 to 4 months	
prevention depression	0	0.8778	0	
treatment choice	0	0.8778	1	Treatment choice should be influenced by: previous treatment history, including the consequences of a relapse, residual symptoms, response to previous treatment and any discontinuation symptoms the person's preference.	
psychosocial interventions	0	0.8772	4	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	
adequate explanation	0	0.8752	1	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	
audio format	0	0.8752	1	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	
clinical language	0	0.8752	1	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	
comprehensive written	0	0.8752	1	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	
independent interpreters	0	0.8752	1	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	
written information	0	0.8752	1	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	
history depression	0	0.8708	0	
symptom profile	0	0.8708	1	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	
risk–benefit ratio	0	0.8586	3	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the risk–benefit ratio is unclear document the rationale for the chosen combination.	
good evidence	0	0.8368	1	This guideline recommends some drugs for indications for which they do not have a UK marketing authorisation at the date of publication, if they are already in use in the NHS for that indication, and there is good evidence to support that use	
severe depression	0	0.8352	12	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	Also consider providing: two sessions per week for the first 2 to 3 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	For people with severe depression, consider providing two sessions per week for the first 2 to 3 weeks of treatment.	Also consider providing: two sessions per week for the first 3 to 4 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	If discontinuation symptoms occur: monitor symptoms and reassure the person if symptoms are mild consider reintroducing the original antidepressant at the dose that was effective (or another antidepressant with a longer half-life from the same class) if symptoms are severe, and reduce the dose gradually while monitoring symptoms. 0 Step 4: complex and severe depression	Teams working with people with complex and severe depression should develop comprehensive multidisciplinary care plans in collaboration with the person with depression (and their family or carer, if agreed with the person)	
effective intervention	0	0.8345	2	The stepped-care model provides a framework in which to organise the provision of services, and supports patients, carers and practitioners in identifying and accessing the most effective interventions (see figure 1)	In stepped care the least intrusive, most effective intervention is provided first; if a person does not benefit from the intervention initially offered, or declines an intervention, they should be offered an appropriate intervention from the next step.	
effective interventions	0	0.8345	1	The stepped-care model provides a framework in which to organise the provision of services, and supports patients, carers and practitioners in identifying and accessing the most effective interventions (see figure 1)	
stepped-care model	0	0.8345	1	The stepped-care model provides a framework in which to organise the provision of services, and supports patients, carers and practitioners in identifying and accessing the most effective interventions (see figure 1)	
functional impairment	0	0.8296	7	In practical terms, clinicians are not expected to switch to DSM-IV but should be aware that the threshold for mild depression is higher than ICD-10 (five symptoms instead of four) and that degree of functional impairment should be routinely assessed before making a diagnosis	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Note that a comprehensive assessment of depression should not rely simply on a symptom count, but should take into account the degree of functional impairment and or disability (see section ).	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	
blood pressure	0	0.8274	9	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	For example: the potential for higher doses of venlafaxine to exacerbate cardiac arrhythmias and the need to monitor the person's blood pressure the possible exacerbation of hypertension with venlafaxine and duloxetine the potential for postural hypotension and arrhythmias with TCAs the need for haematological monitoring with mianserin in elderly people.	
cardiac arrhythmias	0	0.8274	1	For example: the potential for higher doses of venlafaxine to exacerbate cardiac arrhythmias and the need to monitor the person's blood pressure the possible exacerbation of hypertension with venlafaxine and duloxetine the potential for postural hypotension and arrhythmias with TCAs the need for haematological monitoring with mianserin in elderly people.	
elderly people	0	0.8274	1	For example: the potential for higher doses of venlafaxine to exacerbate cardiac arrhythmias and the need to monitor the person's blood pressure the possible exacerbation of hypertension with venlafaxine and duloxetine the potential for postural hypotension and arrhythmias with TCAs the need for haematological monitoring with mianserin in elderly people.	
haematological monitoring	0	0.8274	1	For example: the potential for higher doses of venlafaxine to exacerbate cardiac arrhythmias and the need to monitor the person's blood pressure the possible exacerbation of hypertension with venlafaxine and duloxetine the potential for postural hypotension and arrhythmias with TCAs the need for haematological monitoring with mianserin in elderly people.	
postural hypotension	0	0.8274	1	For example: the potential for higher doses of venlafaxine to exacerbate cardiac arrhythmias and the need to monitor the person's blood pressure the possible exacerbation of hypertension with venlafaxine and duloxetine the potential for postural hypotension and arrhythmias with TCAs the need for haematological monitoring with mianserin in elderly people.	
audio tapes	0	0.818	2	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
competence frameworks	0	0.818	2	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
external audit	0	0.818	2	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
high-quality supervision	0	0.818	2	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
intervention practitioners	0	0.818	0	
outcome measures	0	0.818	2	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
practitioner competence	0	0.818	2	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
regular high-quality	0	0.818	2	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
routine outcome	0	0.818	2	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
treatment adherence	0	0.818	2	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence – for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
prevention psychological	0	0.8136	0	
gmc guidance	0	0.8121	1	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the risk–benefit ratio is unclear document the rationale for the chosen combination.	
off-label medication	0	0.8121	1	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the risk–benefit ratio is unclear document the rationale for the chosen combination.	
primary evidence	0	0.8121	1	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the risk–benefit ratio is unclear document the rationale for the chosen combination.	
unclear document	0	0.8121	1	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the risk–benefit ratio is unclear document the rationale for the chosen combination.	
unusual combinations	0	0.8121	1	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the risk–benefit ratio is unclear document the rationale for the chosen combination.	
inhibitor ssri	0	0.8024	1	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	
potential therapeutic	0	0.8024	1	IPT) behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic benefit.	
psychosocial intervention	0	0.8024	5	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	
regular partner	0	0.8024	1	IPT) behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic benefit.	
relative merits	0	0.8024	1	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	
reuptake inhibitor	0	0.8024	1	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	
selective serotonin	0	0.8024	1	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	
serotonin reuptake	0	0.8024	1	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	
therapeutic benefit	0	0.8024	1	IPT) behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic benefit.	
depression follow-up	0	0.7996	2	Also consider providing: two sessions per week for the first 2 to 3 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	Also consider providing: two sessions per week for the first 3 to 4 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	
cognitive therapy	0	0.7924	3	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Last updated April 2018 the following 6 months. 0 Mindfulness-based cognitive therapy should normally be delivered in groups of 8 to 15 participants and consist of weekly 2-hour meetings over 8 weeks and four follow-up sessions in the 12 months after the end of treatment.	
mindfulness-based cognitive	0	0.7924	3	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Last updated April 2018 the following 6 months. 0 Mindfulness-based cognitive therapy should normally be delivered in groups of 8 to 15 participants and consist of weekly 2-hour meetings over 8 weeks and four follow-up sessions in the 12 months after the end of treatment.	
prevention people	0	0.7897	0	
care mhra	0	0.7787	0	
cost effectiveness	0	0.7787	1	The efficacy and cost effectiveness of cognitive behavioural therapy, interpersonal therapy and 0 The effectiveness of maintenance ECT for relapse prevention in people with severe and recurring	
guideline cg91	0	0.7787	1	NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).	
interpersonal therapy	0	0.7787	1	The efficacy and cost effectiveness of cognitive behavioural therapy, interpersonal therapy and 0 The effectiveness of maintenance ECT for relapse prevention in people with severe and recurring	
maintenance ect	0	0.7787	1	The efficacy and cost effectiveness of cognitive behavioural therapy, interpersonal therapy and 0 The effectiveness of maintenance ECT for relapse prevention in people with severe and recurring	
mhra advice	0	0.7787	1	MHRA advice on valproate: In April 2018, we added warnings that valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place	
place nice	0	0.7787	0	
pregnancy prevention	0	0.7787	1	MHRA advice on valproate: In April 2018, we added warnings that valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place	
prevention plan	0	0.7787	1	MHRA advice on valproate: In April 2018, we added warnings that valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place	
oral contraceptives	0	0.7728	1	Although there is evidence that St John's wort may be of benefit in mild or moderate depression, practitioners should: not prescribe or advise its use by people with depression because of uncertainty about appropriate doses, persistence of effect, variation in the nature of preparations and potential serious interactions with other drugs (including oral contraceptives, anticoagulants and anticonvulsants) advise people with depression of the different potencies of the preparations available and of the potential serious interactions of St John's wort with other drugs.	
bipolar disorder	0	0.7686	1	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	
choosing treatments	0	0.7686	1	Principles for assessment, coordination of care and choosing treatments	
comorbid mental	0	0.7686	1	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	
cultural backgrounds	0	0.7686	1	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	
depression ensure	0	0.7686	1	Last updated April 2018 explore treatment options in an atmosphere of hope and optimism, explaining the different courses of depression and that recovery is possible be aware that stigma and discrimination can be associated with a diagnosis of depression ensure that discussions take place in settings in which confidentiality, privacy and dignity are respected.	
diverse cultural	0	0.7686	1	Be respectful of, and sensitive to, diverse cultural, ethnic and religious backgrounds when working with people with depression, and be aware of the possible variations in the presentation of depression	
diverse ethnic	0	0.7686	1	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	
ensure competence	0	0.7686	1	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	
ethnic differences	0	0.7686	1	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	
explanatory models	0	0.7686	1	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	
mood elevation	0	0.7686	1	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	
physical disorders	0	0.7686	1	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	
religious backgrounds	0	0.7686	1	Be respectful of, and sensitive to, diverse cultural, ethnic and religious backgrounds when working with people with depression, and be aware of the possible variations in the presentation of depression	
sensitive assessment	0	0.7686	1	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	
past history	0	0.7574	6	Therefore it is also important to consider both personal past history and family history of depression when undertaking a diagnostic assessment (see appendix for further details).	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk–benefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	
care plan	0	0.7499	2	Teams working with people with complex and severe depression should develop comprehensive multidisciplinary care plans in collaboration with the person with depression (and their family or carer, if agreed with the person)	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	
care plans	0	0.7499	1	Teams working with people with complex and severe depression should develop comprehensive multidisciplinary care plans in collaboration with the person with depression (and their family or carer, if agreed with the person)	
care professionals	0	0.7499	1	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	
comprehensive multidisciplinary	0	0.7499	1	Teams working with people with complex and severe depression should develop comprehensive multidisciplinary care plans in collaboration with the person with depression (and their family or carer, if agreed with the person)	
crisis plan	0	0.7499	1	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	
multidisciplinary care	0	0.7499	1	Teams working with people with complex and severe depression should develop comprehensive multidisciplinary care plans in collaboration with the person with depression (and their family or carer, if agreed with the person)	
potential triggers	0	0.7499	1	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	
relevant people	0	0.7499	1	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	
social care	0	0.7499	1	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	
individual cbt	0	0.7456	4	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	For all people with depression having individual CBT, the duration of treatment should typically be in the range of 16 to 20 sessions over 3 to 4 months	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	For all people with depression who are having individual CBT for relapse prevention, the duration of treatment should typically be in the range of 16 to 20 sessions over 3 to 4 months	
weeks depression	0	0.7378	0	
practitioners psychological	0	0.7224	0	
cardiovascular disease	0	0.6983	7	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	Erectile dysfunction 3 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 4 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 5 Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications. 6 Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	Erectile dysfunction 3 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 4 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 5 Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications. 6 Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	When prescribing lithium: monitor renal and thyroid function before treatment and every 6 months during treatment (more often if there is evidence of renal impairment) consider ECG monitoring in people with depression who are at high risk of cardiovascular disease	
dependence augmentation	0	0.6983	1	The following strategies should not be used routinely: augmentation of an antidepressant with a benzodiazepine for more than 2 weeks as there is a risk of dependence augmentation of an antidepressant with buspirone , carbamazepine , lamotrigine or valproate as there is insufficient evidence for their use augmentation of an antidepressant with pindolol or thyroid hormones as there is inconsistent evidence of effectiveness .	
disease depression	0	0.6983	0	
high risk	0	0.6983	3	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 0 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 0 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	When prescribing lithium: monitor renal and thyroid function before treatment and every 6 months during treatment (more often if there is evidence of renal impairment) consider ECG monitoring in people with depression who are at high risk of cardiovascular disease	
inconsistent evidence	0	0.6983	1	The following strategies should not be used routinely: augmentation of an antidepressant with a benzodiazepine for more than 2 weeks as there is a risk of dependence augmentation of an antidepressant with buspirone , carbamazepine , lamotrigine or valproate as there is insufficient evidence for their use augmentation of an antidepressant with pindolol or thyroid hormones as there is inconsistent evidence of effectiveness .	
insufficient evidence	0	0.6983	1	The following strategies should not be used routinely: augmentation of an antidepressant with a benzodiazepine for more than 2 weeks as there is a risk of dependence augmentation of an antidepressant with buspirone , carbamazepine , lamotrigine or valproate as there is insufficient evidence for their use augmentation of an antidepressant with pindolol or thyroid hormones as there is inconsistent evidence of effectiveness .	
renal impairment	0	0.6983	1	When prescribing lithium: monitor renal and thyroid function before treatment and every 6 months during treatment (more often if there is evidence of renal impairment) consider ECG monitoring in people with depression who are at high risk of cardiovascular disease	
thyroid function	0	0.6983	1	When prescribing lithium: monitor renal and thyroid function before treatment and every 6 months during treatment (more often if there is evidence of renal impairment) consider ECG monitoring in people with depression who are at high risk of cardiovascular disease	
thyroid hormones	0	0.6983	1	The following strategies should not be used routinely: augmentation of an antidepressant with a benzodiazepine for more than 2 weeks as there is a risk of dependence augmentation of an antidepressant with buspirone , carbamazepine , lamotrigine or valproate as there is insufficient evidence for their use augmentation of an antidepressant with pindolol or thyroid hormones as there is inconsistent evidence of effectiveness .	
antidepressant effect	0	0.6965	1	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	
full antidepressant	0	0.6965	1	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	
gradual development	0	0.6965	1	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	
potential side	0	0.6965	1	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	
remission potential	0	0.6965	1	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	
adequate social	0	0.6655	1	If there is a risk of self-harm or suicide: assess whether the person has adequate social support and is aware of sources of help arrange help appropriate to the level of risk (see section ) advise the person to seek further help if the situation deteriorates.	
social support	1	0.6655	1	If there is a risk of self-harm or suicide: assess whether the person has adequate social support and is aware of sources of help arrange help appropriate to the level of risk (see section ) advise the person to seek further help if the situation deteriorates.	
nice guideline	0	0.6541	22	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss. 1 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	For more information, see the NICE guideline on diabetes in pregnancy. 4 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 5 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	Insulin delivery 8 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	Diabetic foot problems 1 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	NICE guideline on chronic kidney disease in adults.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss. 1 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	For more information, see the NICE guideline on diabetes in pregnancy. 4 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 5 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	Insulin delivery 8 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	Diabetic foot problems 1 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	NICE guideline on chronic kidney disease in adults.	NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	
advance decisions	0	0.6353	1	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	
advance statements	0	0.6353	1	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	
carer support	0	0.6353	1	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	
chronic depression	0	0.6353	1	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	
health act	1	0.6353	1	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	
local family	0	0.6353	1	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	
recurrent severe	0	0.6353	1	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	
verbal information	0	0.6353	1	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	
voluntary organisations	0	0.6353	1	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	
careful monitoring	0	0.6347	1	People who start on low-dose TCAs and who have a clear clinical response can be maintained on that dose with careful monitoring. 0 If the person's depression shows no improvement after 2 to 4 weeks with the first antidepressant, check that the drug has been taken regularly and in the prescribed dose. 1 If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers. 2 If the person's depression shows some improvement by 4 weeks, continue treatment for another 2 to 4 weeks	
clear clinical	0	0.6347	1	People who start on low-dose TCAs and who have a clear clinical response can be maintained on that dose with careful monitoring. 0 If the person's depression shows no improvement after 2 to 4 weeks with the first antidepressant, check that the drug has been taken regularly and in the prescribed dose. 1 If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers. 2 If the person's depression shows some improvement by 4 weeks, continue treatment for another 2 to 4 weeks	
clinical response	0	0.6347	1	People who start on low-dose TCAs and who have a clear clinical response can be maintained on that dose with careful monitoring. 0 If the person's depression shows no improvement after 2 to 4 weeks with the first antidepressant, check that the drug has been taken regularly and in the prescribed dose. 1 If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers. 2 If the person's depression shows some improvement by 4 weeks, continue treatment for another 2 to 4 weeks	
low-dose tcas	0	0.6347	1	People who start on low-dose TCAs and who have a clear clinical response can be maintained on that dose with careful monitoring. 0 If the person's depression shows no improvement after 2 to 4 weeks with the first antidepressant, check that the drug has been taken regularly and in the prescribed dose. 1 If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers. 2 If the person's depression shows some improvement by 4 weeks, continue treatment for another 2 to 4 weeks	
prescribed dose	0	0.6347	1	People who start on low-dose TCAs and who have a clear clinical response can be maintained on that dose with careful monitoring. 0 If the person's depression shows no improvement after 2 to 4 weeks with the first antidepressant, check that the drug has been taken regularly and in the prescribed dose. 1 If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers. 2 If the person's depression shows some improvement by 4 weeks, continue treatment for another 2 to 4 weeks	
significant side	0	0.6347	1	People who start on low-dose TCAs and who have a clear clinical response can be maintained on that dose with careful monitoring. 0 If the person's depression shows no improvement after 2 to 4 weeks with the first antidepressant, check that the drug has been taken regularly and in the prescribed dose. 1 If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers. 2 If the person's depression shows some improvement by 4 weeks, continue treatment for another 2 to 4 weeks	
telephone contact	0	0.6347	2	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	People who start on low-dose TCAs and who have a clear clinical response can be maintained on that dose with careful monitoring. 0 If the person's depression shows no improvement after 2 to 4 weeks with the first antidepressant, check that the drug has been taken regularly and in the prescribed dose. 1 If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers. 2 If the person's depression shows some improvement by 4 weeks, continue treatment for another 2 to 4 weeks	
therapeutic dose	0	0.6347	1	People who start on low-dose TCAs and who have a clear clinical response can be maintained on that dose with careful monitoring. 0 If the person's depression shows no improvement after 2 to 4 weeks with the first antidepressant, check that the drug has been taken regularly and in the prescribed dose. 1 If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers. 2 If the person's depression shows some improvement by 4 weeks, continue treatment for another 2 to 4 weeks	
weekly face-to-face	0	0.6347	1	People who start on low-dose TCAs and who have a clear clinical response can be maintained on that dose with careful monitoring. 0 If the person's depression shows no improvement after 2 to 4 weeks with the first antidepressant, check that the drug has been taken regularly and in the prescribed dose. 1 If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers. 2 If the person's depression shows some improvement by 4 weeks, continue treatment for another 2 to 4 weeks	
collaborative careb	0	0.63	1	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	
combined treatments	0	0.63	1	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	
complex depression	0	0.63	1	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	
complexa depression	0	0.63	1	STEP 4: Severe and complexa depression; risk to life; severe self-neglect	
inadequate response	0	0.63	1	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	
interventions assessment	0	0.63	0	
interventions low-intensity	0	0.63	0	
management nice	0	0.63	1	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	
multiple treatments	0	0.63	1	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	
psychiatric comorbidity	0	0.63	1	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	
psychosocial factors	0	0.63	1	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	
self-neglect depression	0	0.63	0	
severe self-neglect	0	0.63	1	STEP 4: Severe and complexa depression; risk to life; severe self-neglect	
significant psychiatric	0	0.63	1	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	
initial management	0	0.6297	1	Step 1: recognition, assessment and initial management	
mental state	1	0.6297	1	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	
professional depression	0	0.6297	0	
social difficulties	0	0.6297	1	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	
2-hour meetings	0	0.6178	1	Last updated April 2018 the following 6 months. 0 Mindfulness-based cognitive therapy should normally be delivered in groups of 8 to 15 participants and consist of weekly 2-hour meetings over 8 weeks and four follow-up sessions in the 12 months after the end of treatment.	
additional follow-up	0	0.6178	1	If the duration of treatment needs to be extended to achieve remission it should: consist of two sessions per week for the first 2 to 3 weeks of treatment include additional follow-up sessions, typically consisting of four to six sessions over	
delivering psychological	0	0.6178	1	Delivering psychological interventions for relapse prevention	
weekly 2-hour	0	0.6178	1	Last updated April 2018 the following 6 months. 0 Mindfulness-based cognitive therapy should normally be delivered in groups of 8 to 15 participants and consist of weekly 2-hour meetings over 8 weeks and four follow-up sessions in the 12 months after the end of treatment.	
agent lithium	0	0.6106	0	
effects tolerable	0	0.6106	1	People who have had multiple episodes of depression, and who have had a good response to treatment with an antidepressant and an augmenting agent, should remain on this combination after remission if they find the side effects tolerable and acceptable	
good response	0	0.6106	1	People who have had multiple episodes of depression, and who have had a good response to treatment with an antidepressant and an augmenting agent, should remain on this combination after remission if they find the side effects tolerable and acceptable	
long-term maintenance	0	0.6106	1	People with depression on long-term maintenance treatment should be	
maintenance treatment	0	0.6106	1	People with depression on long-term maintenance treatment should be	
multiple episodes	0	0.6106	1	People who have had multiple episodes of depression, and who have had a good response to treatment with an antidepressant and an augmenting agent, should remain on this combination after remission if they find the side effects tolerable and acceptable	
sole agent	0	0.6106	1	Lithium should not be used as a sole agent to prevent recurrence.	
comorbid depression	0	0.5038	1	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	
effective treatment	0	0.5038	3	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	
general measures	0	0.5038	1	General measures	
relevant anxiety	0	0.5038	1	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	
conditions notice-of-rights	0	0.5001	76	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	
depression advice	0	0.4978	1	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
drinking alcohol	0	0.4978	1	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
excess eating	0	0.4978	1	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
offer people	0	0.4978	1	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
physical exercise	0	0.4978	1	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
proper environment	0	0.4978	1	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
regular physical	0	0.4978	1	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
regular sleep	0	0.4978	1	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
sleep hygiene	0	0.4978	1	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
wake times	0	0.4978	1	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
